Baseline characteristics

Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater · Source last updated 2012-10-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      30

   units

   Participants

groups

1. description

   Intravenous Oxaliplatin 130 mg/m\^2, Day 1 + Oral Capecitabine 750 mg/m\^2 twice daily Days 1-14.

   id

   BG000

   title

   Oxaliplatin + Capecitabine

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            lower Limit

            41

            upper Limit

            79

            value

            62

   dispersion Type

   FULL_RANGE

   param Type

   MEDIAN

   title

   Age Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            12

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            18

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

3. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            30

      title

      United States

   param Type

   NUMBER

   title

   Region of Enrollment

   unit Of Measure

   participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice